Fernández-Bañares Fernando, Salas Antonio, Esteve Maria, Espinós Jorge, Forné Montserrat, Viver Josep Maria
Department of Gastroenterology, Hospital Mútua de Terrassa, Barcelona, Spain.
Am J Gastroenterol. 2003 Feb;98(2):340-7. doi: 10.1111/j.1572-0241.2003.07225.x.
Data on collagenous colitis (CC) and lymphocytic colitis (LC) have been based on retrospective studies of registries of patients from multiple hospitals. Such studies may induce a selection of patients with severe forms of the disease, and conclusions about the clinical spectrum of the disease and treatment efficacy are difficult to be drawn. The aim of this study was to compare the clinical features, response to treatment, and long-term follow-up of CC and LC in a large group of patients prospectively diagnosed in a single center.
A specific program was undertaken to prospectively diagnose all patients with microscopic colitis from those referred for a full colonoscopy because of recurrent or chronic diarrhea. Detailed clinical and histological features, response to treatment, and long-term follow-up were compared in patients with confirmed CC and LC.
Thirty-seven patients with CC and 44 with LC were included. Patients with CC were significantly younger and had a significantly longer duration of diarrhea before diagnosis than those with LC. Otherwise, clinical presentation was similar. Drug-induced disease was suspected for ticlopidine, flutamide, gold salts, and bentazepam in LC. Complete resolution of diarrhea was achieved in all patients, spontaneously occurring in nearly 20% of them. Response to salicylates (mainly, mesalazine) was significantly better in LC than in CC (86% vs 42%, p = 0.005). Cholestyramine was highly effective in patients of both groups with concomitant bile acid malabsorption. Patients with CC required prednisone more often than those with LC (30% vs 4.5%, p = 0.005). Both prednisone and budesonide controlled ileal release were highly effective in patients with CC (82% and 89% efficacy). After cessation of diarrhea, 25% of patients with LC and 30% of those with CC relapsed after a mean follow-up of around 3 yr.
CC and LC share a similar clinical picture and have a benign course with long-term cessation of diarrhea in more than 70% of patients. Mesalazine and budesonide seem to be good options as first-line treatment in LC and CC, respectively. Cholestyramine may be a good alternative in patients with concomitant bile acid malabsorption.
关于胶原性结肠炎(CC)和淋巴细胞性结肠炎(LC)的数据一直基于多家医院患者登记处的回顾性研究。此类研究可能会导致选择病情严重的患者,且难以得出关于该疾病临床谱和治疗效果的结论。本研究的目的是前瞻性地比较在单一中心确诊的一大组患者中CC和LC的临床特征、治疗反应及长期随访情况。
开展一项特定计划,对因反复或慢性腹泻而接受全结肠镜检查的所有患者进行前瞻性诊断,以确定所有患有显微镜下结肠炎的患者。对确诊为CC和LC的患者的详细临床和组织学特征、治疗反应及长期随访情况进行比较。
纳入37例CC患者和44例LC患者。CC患者比LC患者显著年轻,且诊断前腹泻持续时间显著更长。除此之外,临床表现相似。在LC中,怀疑替格瑞洛、氟他胺、金盐和苯并二氮杂䓬可导致药物性疾病。所有患者腹泻均完全缓解,近20%的患者为自发缓解。LC患者对水杨酸盐(主要是美沙拉嗪)的反应显著优于CC患者(86%对42%,p = 0.005)。考来烯胺对两组伴有胆汁酸吸收不良的患者均非常有效。CC患者比LC患者更常需要使用泼尼松(30%对4.5%,p = 0.005)。泼尼松和布地奈德控释剂对CC患者均非常有效(有效率分别为82%和89%)。腹泻停止后,平均随访约3年,25%的LC患者和30%的CC患者复发。
CC和LC具有相似的临床表现,病程良性,超过70%的患者腹泻可长期停止。美沙拉嗪和布地奈德似乎分别是LC和CC一线治疗的良好选择。考来烯胺可能是伴有胆汁酸吸收不良患者的良好替代药物。